Barclays Initiates Coverage On Immunome with Overweight Rating, Announces Price Target of $36
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Barclays analyst Lukas Shumway initiates coverage on Immunome (NASDAQ:IMNM) with a Overweight rating and announces Price Target of $36.
Barclays analyst Lukas Shumway initiates coverage on Immunome (NASDAQ:IMNM) with a Overweight rating and announces Price Target of $36.